title: Antidepressant drug development: Focus on triple monoamine reuptake inhibition.
abstract: Many patients with major depressive disorder (MDD) only partially respond, and some have no clinically meaningful response, to current widely used antidepressant drugs. Due to the purported role of dopamine in the pathophysiology of depression, triple-reuptake inhibitors (TRIs) that simultaneously inhibit serotonin (5-HT), norepinephrine (NE) and dopamine reuptake could be a useful addition to the armamentarium of treatments for MDD. A TRI should more effectively activate mesolimbic dopamine-related reward-networks, restore positive mood and reduce potent 5-HT reuptake blockade associated "hypodopaminergic" adverse effects of decreased libido, weight gain and "blunting" of emotions. On the other hand, dopaminergic effects raise concern over abuse liability and TRIs may have many of the cardiovascular effects associated with NET inhibition. Several clinical development programs for potential TRI antidepressants have failed to demonstrate significantly greater efficacy than placebo or standard of care. Successful late-stage clinical development of a TRI is more likely if experimental research studies in the target population of depressed patients have demonstrated target engagement that differentially and dose-dependently improves assessments of reward-network dysfunction relative to existing antidepressants. TRI treatment could be individualized on the basis of predictive markers such as the burden of decreased positive mood symptoms and/or neuroimaging evidence of reward network dysfunction. This review focuses on how the next generation of monoamine-based treatments could be efficiently developed to address unmet medical need in MDD.
authors.affiliation: Isis Pharmaceuticals, Carlsbad, CA, USA rgrln4@gmail.com.
authors.forename: Roger M
authors.initials: RM
authors.lastname: Lane
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use*; D004338:Drug Combinations; D015195:Drug Design; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D018765:Dopamine Uptake Inhibitors; D004338:Drug Combinations; D017367:Selective Serotonin Reuptake Inhibitors
keywords: Abuse liability; decreased positive mood symptoms; dopamine; endophenotype; neurocircuit; predictive enrichment; reward-network; target engagement; translational medicine; treatment resistant depression; triple monoamine reuptake inhibition